Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to discuss the company’s Q1 fiscal 2025 financial results, highlighting its continued focus on growing its portfolio of health-focused products, including Dream Water and LivRelief, which address sleeplessness, chronic pain, and anxiety.
The company reported breakeven adjusted EBITDA of $16 for the quarter, compared to $683 in the same period last year. This was attributed to lower sales due to the timing of purchase orders but was offset by strategic investments in marketing initiatives aimed at expanding brand awareness and equity. Despite the temporary dip, Delivra Health reaffirmed its confidence in achieving year-over-year sales growth for fiscal 2025, driven by ongoing marketing campaigns.
For the quarter ended September 30, 2024, Delivra Health achieved a gross profit of $1,598 with a gross margin of 51%, compared to $1,922 and 52% in the prior year. The decline in gross profit and …